fbpx

News

Lundbeckfonden Ventures News

Gaithersburg, MD, June 15, 2015 - Vtesse, Inc.,  a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the expansion of its Scientific Advisory Board (SAB) and the filling of a key staff position in patient advocacy.  
CANTERBURY, UK, 8 JUNE, 2015 -- Ziarco Group Ltd., a clinical-stage biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Pablo Jimenez, M.D., as Chief Medical Officer, effective immediately. Dr. Jimenez will oversee the clinical development of Ziarco's programs targeting conditions such as atopic dermatitis and psoriasis.
CANTERBURY, UK, 10 JUNE, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced that it has dosed the first patient in its Phase 2a proof-of-concept clinical trial of ZPL-389 in patients with moderate to severe atopic dermatitis at MAC Clinical Research in Manchester, UK. ZPL-389 is the Company's novel, once-daily,...
Expands focus on gram-negative bacteria by adding Potentiator program to pipeline of novel antibiotic compounds.CAMBRIDGE, Mass.- June 8, 2015 -  Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company secured $30M million in a Series A financing.  Lundbeckfond Ventures led the round as a...
Pivotal Rat Study Presented at 2015 Orthopedic Research Society Annual Meeting  Lund, Sweden, (PRNEWSWIRE) May 27, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a pivotal pre-clinical study of CERAMENTT'G as presented at the 2015 Orthopedic Research Society...
South San Francisco, CA - May 12, 2015 - Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology to new therapeutics for retinal disease and cancer, today announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director...
OXFORD, UK - 19 May 2015 - PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody 'armed' series of AbEnAd viruses.
Lund, Sweden, (PRNEWSWIRE) May 13, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received the Frost & Sullivan 2015 Growth Capital Investment Award for outstanding achievement and superior performance in the area of technological innovation and strategic product development in...
Primary endpoint of preventing delayed CINV met with high significanceCambridge, UK - 6th May 2015: Acacia Pharma Ltd (Acacia Pharma" or "the Company"), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention...
1 42 43 44 45 46 66

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV
15. July 2020
Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)
13. July 2020
VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
8. July 2020